SuperGen's Orathecin disappoints in Phase II trial

SuperGen says a Phase II trial of Orathecin plus gemcitabine as a first-line combination therapy for advanced pancreatic cancer patients who have not undergone chemotherapy failed to demonstrate sufficient gains in median survival rates to warrant its advance into a Phase III study. One-year survival statistics were "encouraging," says the company, and Orathecin demonstrated the same safety profile as seen in Phase I.

"We are working with our clinical advisors, investigators and potential partners to evaluate the best options for Orathecin that will maximize this product's potential to help patients in need and realize its commercial value for our stockholders," said James S. Manuso, SuperGen's CEO.

- here's the release for more information